Nurix Therapeutics Inc at JPMorgan Healthcare Conference Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Eric Joseph - JPMorgan - Analyst : Great. Thanks, Arthur. (Conference Instructions) Arthur, maybe just to pick up on the collaboration agreement with -- the GAC collaboration agreement with CGEN, now Pfizer, perhaps I could get you to sort of expand on how this approach sort of complements the activity profile of TPDs alone? I guess, is it a play that would sort of, I guess, the tropism versus with an antibody conjugate, allow for perhaps a better therapeutic window you might achieve with the targeted degrader alone? Or is it more to kind of, perhaps go deeper, or give CGEN -- Pfizer additional optionality where there are already players with their ADC platform?

Question: Eric Joseph - JPMorgan - Analyst : And sorry, and just to clarify the scope of the collaboration, it's primarily just within oncology? Or are there other fields outside of oncology that you might look to explore within the agreement?

Question: Eric Joseph - JPMorgan - Analyst : Great. And so I guess just going back to the update, with your pure BTK degrader, 5948, you presented an update at ASH there, and it is a study where your dose escalation is on ongoing. I guess given the high levels of degradation you're seeing so far at 50 milligrams, I guess, can you talk a little about sort of the -- what's behind the incremental efficacy that you at least seem to be trending towards so far at the higher dose of 100 milligrams, and whether you think that you expect further dose gains, I guess, in efficacy as you continue to dose escalate?

Question: Eric Joseph - JPMorgan - Analyst : I guess in terms of the types of patients that -- you basically have been rolling NHL and CLL separately in parallel with one another. CLL being a little bit behind. Nevertheless, seeing responses in both cohorts. I guess, ultimately, do you anticipate, perhaps, two different doses being pursued? One for CLL, differing from that being pursued in NHL? Or ultimately you'd want to harmonize that with a single dose for both the subpopulations?

Question: Eric Joseph - JPMorgan - Analyst : Maybe just picking up on that final point here with the last question. The deal is very recently signed, I guess, how to think about perhaps just now, perhaps, the first development candidates being brought forward from that collaboration?

Question: Eric Joseph - JPMorgan - Analyst : Is the business development of this sort, this type of thing, something we should expect more of in the next 12 months?

Question: Eric Joseph - JPMorgan - Analyst : Not necessarily DACs, just with the new collaborations with your platform, perhaps another?

Question: Eric Joseph - JPMorgan - Analyst : Okay, excellent. I think we'll leave it there for time. So thanks again, Arthur, and thanks, everybody, for attending.